Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy–related cardiovascular toxicity (CTR-CVT). These complications not only affect physical health but also life expectancy. Risk factors for CTR-CVT include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimize cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Author
Megan Pelter, MD

Important Dates

Date of Release: January 21, 2025
Term of Approval/Date of CME/MOC Expiration: January 20, 2026